After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

Novavax’s COVID-19 vaccine produced higher levels of neutralising antibodies than produced by recovered patients in an early trial, paving the way for a phase 3 trial and potential approval by ...

Respiratory syncytial virus (RSV) is a leading cause ... levels and to elicit a Th1 immune response. Novavax is testing a postfusion F protein vaccine formulated with alum in both older adults ...

US biotech Novavax has begun a phase 1 study of its coronavirus vaccine, as the number in clinical development reached double figures. The World Health Organization has been keeping tabs on ...

According to the FDA, the benefits of vaccination with Abrysvo and Arexvy continue to outweigh the potential risks. The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV ...

Novavax shares are trading lower by 9.8% during Monday's session. Shares of vaccine stocks are trading lower after Moderna issued 2025 revenue guidance below analyst estimates. Next: Access Our ...

Health and pharmaceutical stocks — including Moderna (MRNA), Pfizer (PFE), BioNTech (BNTX), Novavax (NVAX) — are under pressure on Tuesday after Robert F. Kennedy Jr. passed the Senate Finance ...